Development and evaluation of a line probe assay for rapid typing of influenza viruses and detection of the H274Y mutation

Journal of Virological Methods

Volumn 185, Issue 2, 2012, Pages 276-280

  Miyoshi Akiyama, Tohru ^a   Akasaka, Yuki ^b   Oogane, Teruko ^c   Kondo, Yuji ^b   Matsushita, Takeji ^a   Funatogawa, Keiji ^c   Kirikae, Teruo ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b Nipro Corporation   (Japan)

^c Tochigi Prefectural Institute of Public Health and Environmental Science   (Japan)

Author keywords

Influenza virus; Line probe assay; Neuraminidase; Oseltamivir

Indexed keywords

HISTIDINE; OSELTAMIVIR; PYROXYLIN; TYROSINE;

ANTIVIRAL RESISTANCE; ARTICLE; ASSAY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; IMMOBILIZATION; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; LINE PROBE ASSAY; MUTATIONAL ANALYSIS; NONHUMAN; NOSE SMEAR; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SEASONAL INFLUENZA; SENSITIVITY AND SPECIFICITY; VIRUS CULTURE; VIRUS IDENTIFICATION; VIRUS ISOLATION; VIRUS MUTATION; VIRUS STRAIN; VIRUS TYPING;

DNA PROBES; GENES, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MUTATION; REAGENT KITS, DIAGNOSTIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VIRAL PROTEINS;

EID: 84867624868     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2012.06.018     Document Type: Article

References (26)

1. Babu Y., Chand P., Bantia S., Kotian P., Dehghani A., El-Kattan Y., Lin T.H., Hutchison T., Elliott A., Parker C., Ananth S., Horn L., Laver G., Montgomery J. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. Journal of Medicinal Chemistry 2000, 43:3482-3486.
2. Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects 2006, World Medical Association, Ferney-Voltaire, France.
3. Dormitorio T., Giambrone J., Guo K., Hepp G. Detection and characterization of avian influenza and other avian paramyxoviruses from wild waterfowl in parts of the southeastern United States. Poultry Science 2009, 88:851-855.
4. Gubareva L., Kaiser L., Hayden F. Influenza virus neuraminidase inhibitors. Lancet 2000, 355:827-835.
5. Gubareva L., Trujillo A., Okomo-Adhiambo M., Mishin V., Deyde V., Sleeman K., Nguyen H., Sheu T., Garten R., Shaw M., Fry A., Klimov A. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antiviral Therapy 2010, 15:1151-1159.
6. Gubareva L., Webster R., Hayden F. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrobial Agents and Chemotherapy 2001, 45:3403-3408.
7. Hauge S., Dudman S., Borgen K., Lackenby A., Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerging Infectious Diseases 2009, 15:155-162.
8. Hurt A., Holien J., Parker M., Kelso A., Barr I. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. Journal of Virology 2009, 83:10366-10373.
9. Kawachi S., Matsushita T., Sato T., Nunoi H., Noguchi H., Ota S., Kanemoto N., Nakatani K., Nishiguchi T., Yuge A., Imamura H., Kitajima H., Narahara K., Suzuki K., Miyoshi-Akiyama T., Kirikae T. Multicenter prospective evaluation of a novel rapid immunochromatographic diagnostic kit specifically detecting influenza A H1N1 2009 virus. Journal of Clinical Virology 2011, 51:68-72.
10. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., Hayden F., Sugaya N., Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 364:759-765.
11. Lackenby A., Thompson C., Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Current Opinion in Infectious Diseases 2008, 21:626-638.
12. Mercier M., Laperche S., Girault A., Sureau C., Servant-Delmas A. Overestimation of incidence of hepatitis B virus mixed-genotype infections by use of the new line probe INNO-LiPA genotyping assay. Journal of Clinical Microbiology 2011, 49:1154-1156.
13. Morgan M., Kalantri S., Flores L., Pai M. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infectious Diseases 2005, 5:62.
14. Nakatani S., Santos C., Riediger I., Krieger M., Duarte C., Lacerda M., Biondo A., Carrilho F., Ono-Nita S.K. Development of hepatitis C virus genotyping by real-time PCR based on the NS5B region. PLoS ONE 2010, 5:e10150.
15. Nakauchi M., Ujike M., Obuchi M., Takashita E., Takayama I., Ejima M., Oba K., Konomi N., Odagiri T., Tashiro M., Kageyama T. Rapid discrimination of oseltamivir-resistant 275Y and -susceptible 275H substitutions in the neuraminidase gene of pandemic influenza A/H1N1 2009 virus by duplex one-step RT-PCR assay. Journal of Medical Virology 2011, 83:1121-1127.
16. Neumann G., Noda T., Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009, 459:931-939.
17. Operario D., Moser M., St George K. Highly sensitive and quantitative detection of the H274Y oseltamivir resistance mutation in seasonal A/H1N1 influenza virus. Journal of Clinical Microbiology 2010, 48:3517-3524.
18. Renaud C., Kuypers J., Englund J. Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1. Journal of Clinical Virology 2011.
19. Rossau R., Traore H., De Beenhouwer H., Mijs W., Jannes G., De Rijk P., Portaels F. Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin. Antimicrobial Agents and Chemotherapy 1997, 41:2093-2098.
20. Sekiguchi J., Nakamura T., Miyoshi-Akiyama T., Kirikae F., Kobayashi I., Augustynowicz-Kopec E., Zwolska Z., Morita K., Suetake T., Yoshida H., Kato S., Mori T., Kirikae T. Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant mycobacterium tuberculosis strains. Journal of Clinical Microbiology 2007, 45:2802-2807.
21. Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine 1999, 17(Suppl. 1):S3-S10.
22. Smith G.J., Vijaykrishna D., Bahl J., Lycett S., Worobey M., Pybus O., Ma S., Cheung C., Raghwani J., Bhatt S., Peiris J., Guan Y., Rambaut A. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009, 459:1122-1125.
23. Thompson W., Comanor L., Shay D. Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease. Journal of Infectious Diseases 2006, 194(Suppl. 2):S82-S91.
24. Ujike M., Ejima M., Anraku A., Shimabukuro K., Obuchi M., Kishida N., Hong X., Takashita E., Fujisaki S., Yamashita K., Horikawa H., Kato Y., Oguchi A., Fujita N., Tashiro M., Odagiri T. Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010. Emerging Infectious Diseases 2011, 17:470-479.
25. Yamashita M. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza. Antiviral Chemistry and Chemotherapy 2010, 21:71-84.
26. Zambon M., Hayden F. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Research 2001, 49:147-156.